LONDON and BANGKOK, Thailand, July 3 (Bernama-GLOBE NEWSWIRE) — Aztiq Pharma Partners (“Aztiq”), a private equity company focused on the life sciences sector, and Innobic (Asia) Company Limited (“Innobic”), the life science arm of Thai oil and gas conglomerate PTT Public Company Limited (“PTT”) (collectively, “the shareholders”), today announced the pricing of a sale of 25,095,850 shares of Lotus Pharmaceuticals (1795:TT; “Lotus,” “the company”), a multinational pharmaceutical company, at a price of NT$297 per share. The trade will be settled on July 5, 2023, subject to satisfaction of customary settlement procedures. The sale is being executed by Alvogen Emerging Market Holdings Limited (“AEMH”), which will continue to own 41% of Lotus common stock after the close of the transaction. Inclusive of Innobic’s direct holdings of Lotus, the shareholders will continue to own approximately 47.7% of the company.
- July 3, 2023
0
222
Less than a minute
You can share this post!
administrator
Related Articles
Unbelievable Jeff! IriusRisk Introduces an AI-powered Tool Which…
- October 22, 2024
EBC Financial Group Expands Partnership with DiNapoli’s Leading…
- October 22, 2024
Quantexa Recognized as Category Leader in the RiskTech…
- October 22, 2024